RECALL ALERT – -VETERINARY DRUG PRODUCTS DECLARED SUBSTANDARD BY PROVINCIAL DRUG TESTING LABORATORIES.

Recall Alert

VETERINARY DRUG PRODUCTS DECLARED SUBSTANDARD BY PROVINCIAL DRUG TESTING LABORATORIES.

DRAP Alert NoNo I/S/09-25-71
Action Date17 September, 2025.
Target Audience·         National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
·         Healthcare Professionals-Veterinarians
·         Farmers/consumers
Problem / Issue Drug Testing Laboratories from Provinces informed the Drug Regulatory Authority of Pakistan that the samples of below mentioned Veterinary products have been declared as ‘Substandard’.

Therapeutic Goods (s) Affected: –

S#Product DetailsBatch #Manufacturer detailsRemarks
1INJECTION VARIAX 100ML  
EACH ML CONTAINS:
VITAMIN A 15.000 I ,
VITAMIN D3 1,000 IU,
VITAMIN E 20MG,
VITAMIN B1 10MG,
VITAMIN B SODIUM PHOSPHATE 5MG,
VITAMIN B6 3MG.
NICOTINAMIDE 35MG,
PANTOTHENOL 25MG,
VITAMIN B12 50MCG
EI-1654  M/s. Eterna Pharma (Pvt) Ltd.   Plot No. 99, 100, 101 &198-C, Sector D1, Old Industrial Estate, Mirpur, AJK Pakistan. (DML # 000923) ‘Adulterated’ with respect to Assay test performed for Vìtamin B1 and is “Adulterated” as defined under clause (iv) of sub-section (a) of section 3 of The Drugs Act, 1976 as it contains Ascorbic Acid, Ambrosic Acid and Peiminine as ingredients other than the labelled ingredients.  
2Ivermex Injection 100 mL
Each ml contains Ivermectin …. 10 mg
IV348M/s Wimits Pharmaceuticals (Pvt) Ltd. Plot No. 129 Sundar Industrial Estate Lahore. (DML # 000789) ‘Substandard’ quality on the basis of the result of test for related substance, sterility & assay of Ivermectin.  
3PRIMOX injectable suspension 50mL
Each ml contains
amoxicillin (as trihydrate) …. 150 mg
PP9789M/s Prix Pharmaceutical (Pvt) Ltd.   Plot No. 5 Pharmacity 30-Km Multan Road Lahore. (DML # 000587) ‘Substandard’ quality on the basis of the result of sterility test.
4Injection Lumpyvac 50  
After reconstitution, each 2ml dose contains:
Attenuated Lumpy Skin Disease Virus (Neethling strain) ……. ≥103.5 TCID50    

Diluent for Lumpy Skin Disease Vaccine for Cattle (For Veterinary Use)
Potassium Chloride 0.2mg
Potassium Phosphate monobasic 0.2 mg
Sodium Chloride 0.8mg,
Sodium Phosphate dibasic 1.14mg per 2 mL (Reg # 111128)  
25/LSD/01Importer: M/s Huzaifa International. Commercial Area, Aziz Bhatti Town, Dist. Sargodha. Manufacturer: Vetal animal Health Product S.A Organize Sanayi Bolgesi, Petrol Mah. 14. Cad. No. 01, Adiyamam, Turkey   ‘Substandard’ on the basis of the result of sterility test.
5  Injection Oxytocin 50ml Oxytocin 10 IU/Ml
Reg# 014564  
V-06725M/s Venus Pharma. 23-Km Multan Road. Lahore. (DML # 000300)‘Substandard’ on the basis of the result of sterility test.
6Injection Oxytovetz 50ml Oxytocin (USP) … 10 IU/mL
Reg. # 111468
25129639
M/s Vetz Pharmaceutical (Pvt) Ltd. Plot No. Q-1 SITE Kotri Sindh (DML # 000813)
‘Substandard’ on the basis of the result of sterility test.
Risk Statement:Use of the above-mentioned veterinary drug products poses serious risks to animal health and public safety:
·   Treatment failure and loss of therapeutic efficacy in livestock.
·   Microbial contamination leading to sepsis and animal deaths.
·   Ineffective vaccination against Lumpy Skin Disease, increasing risk of outbreaks.
·   Adverse economic impact on farmers due to animal health losses.
Food safety risks through compromised milk and meat supply chains.
Action Initiated– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market.

– All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company.

Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsmsdra.gov.pk.

Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for VeterinarianThis alert applies strictly to the specific batches listed above and does not apply to other batches of the same products. Veterinarians are therefore advised not to prescribe, administer, or stock these identified batches under any circumstances. In case any of the above-mentioned batches have already been administered, treated animals should be closely monitored for possible signs of infection, treatment failure, or adverse reactions, and appropriate supportive care must be provided. Any suspected adverse events or quality-related problems linked to these batches should be reported immediately to DRAP’s Pharmacovigilance Centre and to the Provincial Livestock & Dairy Development Departments. Practitioners are further advised to ensure that only alternative registered and quality-assured batches are used in veterinary practice.
Advice for Farmers and Livestock OwnersFarmers, dairy owners, and animal keepers are strictly advised not to use these identified batches for their cattle or other livestock, as they may cause serious illness, infection, treatment failure, or even death in animals. If any of these batches have already been given, animals should be observed carefully for unusual symptoms such as fever, weakness, swelling at the injection site, or lack of recovery, and immediate veterinary assistance should be sought. Farmers are further advised to return such products to their supplier and use only safe, registered, and quality-assured veterinary medicines and vaccines to protect the health of their animals and avoid financial losses.

SPURIOUS / FALSIFIED MEDICINE DETECTED – DAIZELIVE INJECTION 2ML (DIAZEPAM 10MG/2ML, CLAIMED)

Rapid Alert

SPURIOUS / FALSIFIED MEDICINE DETECTED – DAIZELIVE INJECTION 2ML (DIAZEPAM 10MG/2ML, CLAIMED)

DRAP Alert NoNo I/S/09-25-70
Action Date17th September, 2025
Target Audience1. Regulatory Field Force of DRAP and Provincial Drug Control departments.
2. Healthcare Professionals
3. Pharmacies and medical stores
Problem StatementDirectorate of Drugs Control Punjab informed Drug Regulatory Authority of Pakistan that the samples of below mentioned products have been declared as ‘Spurious’.

The product identification details are as under: –

Therapeutic Good Affected:-

S#Product NameBatch No.ManufacturersRemarks
1.Injection Daizelive 2ml   Each 2ml ampoule contains: Diazepam …… 10 mgDZ44M/s Liven Pharmaceuticals (Pvt) Ltd. Sray Road, 49 KM, Multan Road, Phool Nagar, District Kasur (DML # 000881)Drug Testing Laboratory, Rawalpindi has declared the sample as ‘spurious’ since it does not contain the claimed active ingredient (Diazepam) and instead contains an undeclared ingredient (Chlorpheniramine Maleate 45.283 mg/2ml).
Risk StatementLaboratory testing has confirmed that the product labeled as Daizelive Injection 2ml (Diazepam 10mg/2ml) is spurious/falsified, as it does not contain Diazepam, instead contains Chlorpheniramine Maleate (45.283mg/2ml).
Use of this falsified product poses a serious and life-threatening risk, particularly for patients requiring Diazepam for seizures, severe anxiety, or emergency care, as they will not receive the intended treatment.
Healthcare professionals and the public are strongly advised to immediately discontinue use of this product, ensure recall compliance, and report any suspected adverse outcomes or suspicious stock to DRAP.
Action InitiatedThe Regulatory Field Force has been directed to conduct surveillance activities to confiscate the abovementioned falsified product.

All Pharmacists, chemists, and other healthcare professionals working at distributions, pharmacies, healthcare facilities, and other aspects of the supply chain system should immediately check the stock, and information related to the suppliers of such products should be provided to the Regulatory field force (DRAP, Provincial Drug Control Departments) to ensure the removal of these product from the circulation.
Advice for Healthcare ProfessionalsDRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link.  Further information on reporting problems to DRAP is available on this link.
Advice for ConsumersConsumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre.

All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

Recall Alert – DRUG PRODUCTS DECLARED SUBSTANDARD BY PROVINCIAL DRUG TESTING LABORATORIES.

Recall Alert

DRUG PRODUCTS DECLARED SUBSTANDARD BY PROVINCIAL DRUG TESTING LABORATORIES.

DRAP Alert NoNo I/S/09-25-69
Action Date15 September, 2025.
Target Audience– National Regulatory Field Force.
– Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics
– General Public
Problem / Issue Drug Testing Laboratories from Provinces informed the Drug Regulatory Authority of Pakistan that the samples of below mentioned products have been declared as ‘Substandard’.

Therapeutic Goods (s) Affected: –

S#Product NameBatch No.ManufacturersRemarks
1SN DOL Suspension 60ml.   Each 5ml contains: Paracetamol ……… 120 mg917M/s SNB Pharma (Pvt) Ltd. Plot No. 142 Industrial Estate Hayatabad Peshawar. (DML # 000759)‘Substandard’ on the basis of presence of impurity (Ethylene Glycol), above the permissible limit.
2SALBOVENT Oral syrup 60ml   Each 5ml contains Salbutamol (as sulphate) .. 2mgL25D52M/s Synchro Pharmaceuticals. 77-Industrial Estate Kot Lakhpat Lahore. (DML # 000575)‘Substandard’ on the basis of presence of impurity (Ethylene Glycol), above the permissible limit.
3RESGYL Suspension 60 ml   Each 5ml contains Benzoyl Metronidazole equivalent to Metronidazole ………… 200 mg  4E566M/s Rasco Pharma (Pvt) Ltd. 5.5 Km Raiwind Road Ali Razabad, Lahore. (DML # 000530)‘Substandard’ on the basis of presence of impurity (Ethylene Glycol), above the permissible limit.
4Tablet Daisy 10 mg   Each film coated tablet contains Cetirizine Dihydrochloride USP ………………………….10mg  258084 & 258085  M/s Mega Pharmaceuticals Ltd. 27 Km Raiwind Road Lahore (DML # 000537)‘Substandard’ on the basis of Test for impurities (Organic impurities).
5Colchis Capsules   Each Hard Gelatin Capsule contains: Thiocolchicoside ……….4 mg15M/s Akson Pharmaceuticals (Pvt) Ltd. Plot No. 9B-1 & 2 Sector D-1 Old Industrial Estate Mirpur Azad Kashmir. (DML # 000486)‘Substandard’ on the basis of Assay and uniformity of weight.
6AQUA-P Injection (Sterile Water for Injection 5mL)  P-676 P-677M/s Ipram International. Plot # 26 SS-3 National Industrial Zone Rawat. (DML # 000551)Drug Testing Laboratory, Lahore declared the sample as ‘substandard’ quality on the basis of the result of test for bacterial endotoxins.
7Sterile Water for Injection 10ml   Each Glass Ampoule contains: WFI …………………. 10mL084L24M/s Brookes Pharma (Pvt) Ltd. Plot No. 58-59 Sector No. 15 Korangi Industrial Area Karachi. (DML # 000275)‘Substandard’ on the basis of Bacterial Endotoxins Test.
8Sterile Water for injection 5 ml   Each Glass Ampoule contains: WFI …………………. 5 ml  130M/s Wilshire Laboratories (Pvt) Ltd. 124/1 Industrial Estate Kot Lakhpat Lahore. (DML # 000232)‘Substandard’ on the basis of Bacterial Endotoxins Test.  
Risk Statement:The above drug products have been declared substandard / adulterated due to toxic impurities, undeclared ingredients, assay failures, sterility issues, and bacterial endotoxins. Their use may cause treatment failure, harmful side effects, or serious health risks including infections and toxicity. Children, elderly, hospitalized, and immunocompromised patients are at greater risk. The public and healthcare providers are advised to stop use and return the affected batches immediately.
Action Initiated– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market.

– All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company.

Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsmsdra.gov.pk.

Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare ProfessionalsDRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product.  

-Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the
Adverse Event Reporting Form or online through this link.

-Please click here for further information on problem reporting to DRAP.
Advice for Consumers-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product.

-All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

RAPID ALERT – CRACKDOWN AGAINST FALSIFIED / SPURIOUS PRODUCTS

Rapid Alert

CRACKDOWN AGAINST FALSIFIED / SPURIOUS PRODUCTS

DRAP Alert NoNo I/S/09-25-68
Action Date17th September, 2025
Target Audience1. Regulatory Field Force of DRAP and Provincial Drug Control departments.
2. Healthcare Professionals
3. Pharmacies and medical stores
Problem StatementDrug testing Laboratories from Provinces have informed the Drug Regulatory Authority of Pakistan that the samples of below mentioned products have been declared ‘Spurious’ as its packaging falsely claims that it was manufactured by a licensed pharmaceutical company whereas it was not. The details of reports are as under:

The product identification details are as under: –

Therapeutic Good Affected:-

S#Product NameBatch No.Purported ManufacturerRemarks
1.Azomax 500mg (Azithromycin 500mg)C1699Purported to be manufactured by AGP Limited KarachiSpurious (Does not contain active ingredient)
2.Klaricid 500mg tablet (Clarithromycin 500mg)722269XVPurported to be manufactured by Abbott Laboratories KarachiSpurious (Does not contain active ingredient)
Risk StatementAll the above mentioned purported drug products are confirmed as falsified/spurious, as its packaging falsely claims that it was manufactured by a licensed pharmaceutical company whereas it was not. Laboratory testing has revealed that the product contains no active pharmaceutical ingredient, resulting in complete lack of therapeutic effect. Such falsification poses a serious risk to public health, potentially leading to treatment failure, disease progression, and even life-threatening outcomes, particularly for patients relying on these medications for critical care. The public is strongly advised not to use these purported drug products and to report any suspicious or unverified medicines to DRAP immediately.
Action InitiatedThe Regulatory Field Force has been directed to conduct surveillance activities to confiscate the abovementioned Un-Registered/falsified product.

All Pharmacists, chemists, and other healthcare professionals working at distributions, pharmacies, healthcare facilities, and other aspects of the supply chain system should immediately check the stock, and information related to the suppliers of such products should be provided to the Regulatory field force (DRAP, Provincial Drug Control Departments) to ensure the removal of these product from the circulation.
Advice for Healthcare ProfessionalsDRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link.  Further information on reporting problems to DRAP is available on this link.
Advice for ConsumersConsumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre.

All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

RAPID ALERT – CRACKDOWN AGAINST UNLICENSED / UNAUTHORIZED MANUFACTURERS

Rapid Alert

CRACKDOWN AGAINST UNLICENSED / UNAUTHORIZED MANUFACTURERS

DRAP Alert NoNo I/S/09-25-67
Action Date17th September, 2025
Target Audience1. Regulatory Field Force of DRAP and Provincial Drug Control departments.
2. Healthcare Professionals
3. Pharmacies and medical stores
Problem StatementDrug testing Laboratories from Provinces have informed the Drug Regulatory Authority of Pakistan that the samples of below mentioned products have been declared ‘Spurious’ as its packaging falsely claims that it was manufactured by a licensed pharmaceutical company whereas it was not. The details of reports are as under:

The product identification details are as under: –

Therapeutic Good Affected:-

S#Product NameBatch No.Purported ManufacturerRemarks
 Dytron Tabelt 10mg (Dydrogesterone 10mg)D1TPurported to be manufactured by an unlicensed /illegal entity claimed to be Pax Pharmaceuticals KarachiSpurious (Does not contain active ingredient)
 Levontis 375mg (Amoxicillin trihydrate: 250, Clavulanic Acid: 125mg)LF2-do-Spurious (Does not contain active ingredient)
 Levontis 625mg (Amoxicillin trihydrate: 500, Clavulanic Acid: 125mg)LF2-do-Spurious (Does not contain active ingredient)
 Levontis 625mg (Amoxicillin trihydrate: 875, Clavulanic Acid: 125mg)LF4-do-Spurious (Does not contain active ingredient)
 Sulfira suspension (Sucralfate 1g/5ml)SL6-do-Spurious (Does not contain active ingredient)
 Furin 50mcg aerosol spray (Mometasone Furoate 50mcg)NF4-do-Spurious (Does not contain active ingredient)
 Droxel capsule 500mg (Cefadroxil Monohydrate 500mg))RC5-do-Spurious (Does not contain active ingredient)
 Bromiz tablet (Bromazepam 3mg)0007Purported to be manufactured by an unlicensed /illegal entity claimed to be Miraz Pharma Kasur (Fictitious firm)Spurious (Does not contain active ingredient)
Risk StatementAll the above mentioned purported drug products are confirmed as falsified/spurious, as its packaging falsely claims that it was manufactured by a licensed pharmaceutical company whereas it was not. Laboratory testing has revealed that the product contains no active pharmaceutical ingredient, resulting in complete lack of therapeutic effect. Such falsification poses a serious risk to public health, potentially leading to treatment failure, disease progression, and even life-threatening outcomes, particularly for patients relying on these medications for critical care. The public is strongly advised not to use these purported drug products and to report any suspicious or unverified medicines to DRAP immediately.
Action InitiatedThe Regulatory Field Force has been directed to conduct surveillance activities to confiscate the abovementioned Un-Registered/falsified product.

All Pharmacists, chemists, and other healthcare professionals working at distributions, pharmacies, healthcare facilities, and other aspects of the supply chain system should immediately check the stock, and information related to the suppliers of such products should be provided to the Regulatory field force (DRAP, Provincial Drug Control Departments) to ensure the removal of these product from the circulation.
Advice for Healthcare ProfessionalsDRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link.  Further information on reporting problems to DRAP is available on this link.
Advice for ConsumersConsumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre.

All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

Falsified Vigamox® Ophthalmic Solution – Batch VHF02A (Not from Authorized Source)

Rapid Alert

Falsified Vigamox® Ophthalmic Solution – Batch VHF02A (Not from Authorized Source)

DRAP Alert NoNo I/S/09-25-66
Action Date17th September, 2025
Target Audience1. Regulatory Field Force of DRAP and Provincial Drug Control departments.
2. Healthcare Professionals
3. Pharmacies and medical stores
Problem StatementNovartis Pharma (Pakistan) Ltd., Karachi informed DRAP that falsified Vigamox® Sterile Ophthalmic Solution bearing Batch # VHF02A is identified in the Pakistani market. The reported batch number is not imported, manufactured, or supplied by Novartis Pharma (Pakistan) Ltd., i.e. the genuine registration holder in Pakistan. The packaging falsely uses the Novartis name and branding, but it does not come from the authorized supply chain.
Please click downlaod button on top of page for Rapid Alert with pictorial guidance to identify the falsified comparsion with original product.
Risk StatementIn the case of Vigamox® (Batch No. VHF02A), such falsification may result in ineffective treatment of bacterial eye infections, potential worsening the infection, and risk of serious eye damage or vision loss. This alert applies only to Batch No. VHF02A and does not affect other batches of Vigamox® in the market supplied by the authorized registration holder. The falsified batch poses a particular risk to patients with eye infections, especially children, the elderly, and those with weakened immune systems, who may experience rapid deterioration if untreated or improperly treated.
Action InitiatedThe Regulatory Field Force has been directed to conduct surveillance activities to confiscate the abovementioned falsified product.

All Pharmacists, chemists, and other healthcare professionals working at distributions, pharmacies, healthcare facilities, and other aspects of the supply chain system should immediately check the stock, and information related to the suppliers of such products should be provided to the Regulatory field force (DRAP, Provincial Drug Control Departments) to ensure the removal of these product from the circulation.
Advice for Healthcare ProfessionalsDRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link.  Further information on reporting problems to DRAP is available on this link.
Advice for ConsumersConsumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre.

All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

Recall Alert: Lipidem® / Lipoplus® Emulsion for Infusion (Product Stability Risk)

Recall Alert

Lipidem® / Lipoplus® Emulsion for Infusion (Zone IV Stability Risk for Pakistan)

DRAP Alert NoNo I/S/09-25-65
Action Date17 September, 2025.
Target Audience·         Hospitals (Public & Private): especially those with ICU, surgical, oncology, and nutrition support units.
·         Parenteral Nutrition Centre / Clinical Nutrition Teams: where lipid emulsions are routinely administered.
·         Pharmacists: particularly hospital pharmacists and those in charge of sterile/IV admixtures.
·         Physicians: especially intensivists, anesthesiologists, gastroenterologists, and pediatricians using parenteral nutrition.
·         Provincial Health Authorities & Regulatory Bodies: to ensure monitoring and enforcement at the provincial level.
·         Importer & Distributors: of Lipidem® / Lipoplus® in Pakistan.
·         Nursing Staff: involved in IV infusion preparation and administration.
Problem / Issue Stability studies conducted by the manufacturer and German regulatory authority identified droplet-like agglomerates (subvisual fat particles) in Lipidem® / Lipoplus® emulsions stored at 25°C beyond 12 months. These agglomerates, if infused without appropriate filtration, may lead to serious adverse events, including fat embolism in pulmonary capillaries. The details of the product is as under: –

Therapeutic Goods (s) Affected: –

S#Reg. #Name of Drug(s) & CompositionPackingShelf LifeImporter details
1.099492Lipoplus Emulsion for Intravenous Infusion
Each 1000 ml contains:
Medium chain triglycerides…. 100gm
Soya oil …………………… 80gm
Omega-3-acid triglycerides… ….20gm
(As per Innovator’s Specification)*
250m1 Glass Bottle02 yearsM/s B.Braun Pakistan (Pvt) Ltd, The Forum, Suite 216 Khayaban-e-Jami, Clifton Block 9, Karachi.   Godown address: Ground Floor Plot No. C-153, S-6F, Mehran Town, Karachi.
Risk Statement:In stability studies conducted in Germany, droplet-like agglomerates were detected in Lipidem® / Lipoplus® emulsions stored at 25 °C beyond 12 months. To mitigate this risk under those conditions, the German authority recommended the use of a 1.2 µm lipid infusion filter during administration.

Since Pakistan falls under Zone IV climatic conditions (hot and humid), which differ significantly from Germany (25°C), the risk of earlier onset of agglomerate formation cannot be excluded. To date, no stability information or scientific justification for Zone IV conditions has been provided by the manufacturer or Marketing Authorization Holder (MAH). Considering these factors and the higher temperature and humidity in Pakistan, the matter is classified as a Class I recall risk, as the defect may reasonably be expected to cause serious adverse health consequences if not managed appropriately.
Action Initiated– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market.

– All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company.

Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsmsdra.gov.pk.

Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare ProfessionalsDRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product.  

-Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the
Adverse Event Reporting Form or online through this link.

-Please click here for further information on problem reporting to DRAP.
Advice for Consumers-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product.

-All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

Recall Alert (Class-II) – Drug Products Declared substandard by Directorate of Drugs Control Punjab (DDCP)

Recall Alert

DRAP Alert NoNo II/S/09-25-64
Action Date15 September, 2025.
Target Audience– National Regulatory Field Force.
– Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics
– General Public
Problem / Issue Directorate of Drugs Control Punjab (DDCP) informed the Drug Regulatory Authority of Pakistan that the samples of below mentioned products have been declared as ‘Substandard’.

Therapeutic Goods (s) Affected: –

S#Product NameBatch No.ManufacturersRemarks
1.Tablet Ortizin 10mg   Each film coated tablet contains: Cetirizine 2HCl ……10 mg    24L377M/s Obsons Pharmaceuticals. 209-S Industrial Estate Kot Lakhpat Lahore. (DML # 000416)DDCP Alert No. l72/2025 declared the sample as ‘substandard’ on the basis of assay and impurities testing.
2.Tablet Daisy 10 mg   Each film coated tablet contains:  Cetirizine 2HCl ……10 mg  25B084 & 25B085  M/s Mega Pharmaceuticals Ltd.   27 Km Raiwind Road Lahore. (DML # 000537)DDCP Alert No. l72/2025 declared the sample as ‘substandard’ on the basis of impurities testing (Organic impurities).
3.Tablet Ascard 75   Each enteric coated tablet contains: Acetyl Salicylic acid …. 75 mg  AR076K  M/s Atco Laboratories Limited.   B-18 S.I.T.E Karachi. (DML # 000188)DDCP Alert No. l73/2025 declared the sample as ‘substandard’ on the basis of test for related substance (Impurity C: Salicylic Acid).
4.Tablet Bytec 10mg   Each film coated tablet contains:  Cetirizine 2HCl ……10 mg  E604, E605 & E606  M/s Batala Pharmaceuticals. 23/B Small Industrial Estate No. 2 Gujranwala. (DML # 000477)DDCP Alert No. l79/2025 declared the sample as ‘substandard’ on the basis of impurities testing.
5.Tablet Vivin 10 mg   Each film coated tablet contains:  Cetirizine 2HCl ……10 mg315M/s Murfy Pharmaceuticals (Pvt) Ltd. 8-Km Raiwind Road Lahore. (DML # 000543)DDCP Alert No. l79/2025 declared the sample as ‘substandard’ on the basis of impurities testing.
Risk Statement:The above-mentioned batches of tablets have been declared substandard due to failure in assay and impurities testing, including elevated levels of related substances. Use of these defective medicines may lead to reduced therapeutic effect, unpredictable side effects, and potential toxicity.
Patients, pharmacists, and healthcare providers are advised to discontinue the affected batches immediately and report any adverse events to DRAP.
Action Initiated– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market.

– All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company.

Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsmsdra.gov.pk.

Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare ProfessionalsDRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product.  

-Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the
Adverse Event Reporting Form or online through this link.

-Please click here for further information on problem reporting to DRAP.
Advice for Consumers-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product.

-All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

Recall Alert (Class-I) – Drug Products declared substandard by Directorate of Drugs Control Punjab (DDCP)

Recall Alert

DRAP Alert NoNo I/S/09-25-63
Action Date15 September, 2025.
Target Audience– National Regulatory Field Force.
– Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics
– General Public
Problem / Issue Drug Testing Laboratories from Provinces informed the Drug Regulatory Authority of Pakistan that the samples of below mentioned products have been declared as ‘Substandard’.

Therapeutic Goods (s) Affected: –

S#Product NameBatch No.ManufacturersRemarks
1STERILE OPHTHALMIC SUSPENSION 5 ML BROMYCIN-D   Each ml contains: TOBRAMYCIN 3MG, DЕХАМЕТHASONE 1MG    6892M/s Innvotek Pharmaceuticals. Plot No.35 Industrial Estate Kahuta Triangle Islamabad. (DML # 000487)Drug Testing Laboratory, Rawalpindi declared the sample as ‘substandard’ quality on the basis of the result of Sterility test.
2.Injection Metrorise   Each 100ml vial contains: Metronidazole USP … 500mg (0.5% w/v)  LV-2504  M/s Pak Risen Pharmaceuticals. Plot No. 3 Block B Phase-I-II Industrial Estate Hattar. (DML # 000573)  Drug Testing Laboratory, Bahawalpur declared the sample as ‘substandard’ quality on the basis of the result of Bacterial Endotoxin test.  
3.Sterile water for injection 5ml   Each glass ampoule contains Sterile water for injection 5ml    24L608  M/s Medisave Pharmaceuticals. Plot No.578-579 Sundar Industrial Estate Lahore. (DML # 000681)  DDCP Alert No. l72/2025 declared the sample as ‘substandard’ on the basis of the result of Bacterial Endotoxin test.  
4.Sterile water for injection 5 ml   Each glass ampoule contains Sterile water for injection 5ml25WF01  M/s Friends Pharma (Pvt) Ltd. 31-Km Ferozepur Road Lahore. (DML # 000681)  DDCP Alert No. l72/2025 declared the sample as ‘substandard’ on the basis of visible particulate matter.  
5.ELPOMIDE INJ 10mg/2ml   Metoclopramide HCl BP 10mg/2ml  332  M/s Elite Pharma (Pvt) Ltd. 9.5 Km Sheikhupura Road Lahore. (DML # 000455)  DDCP Alert No. l72/2025 declared the sample as ‘substandard’ on the basis of visible particulate matter.
6.Injection Aqua-P 5ml Each glass ampoule contains Sterile water for injection 5ml P-672  M/s Ipram International. Plot # 26 SS-3 National Industrial Zone Rawat. (DML # 000551)  DDCP Alert No. l72/2025 declared the sample as ‘substandard’ on the basis of visible particulate matter.  
7.Water for injection 5 ml Sterile water for injection 5ml.  130  M/s Wilshire Laboratories (Pvt) Ltd.  124/1 Industrial Estate Kot Lakhpat Lahore. (DML # 000232)  DDCP Alert No. l72/2025 declared the sample as ‘substandard’ on the basis of the result of Bacterial Endotoxin test.  
8.Sterile water for injection 10 ml   Each glass ampoule contains Sterile water for injection 10 ml  084L24  M/s Brookes Pharma (Pvt) Ltd.   Plot No. 58-59 Sector No. 15 Korangi Industrial Area Karachi. (DML # 000275)  DDCP Alert No. l72/2025 declared the sample as ‘substandard’ on the basis of the result of sterility test.  
9.Syrup Salbovent 60ml   Each 5ml contains: Salbutamol (as sulphate) …… 2mg  L25D52  M/s Synchro Pharmaceuticals.  77-Industrial Estate Kot Lakhpat Lahore. (DML # 575)  DDCP Alert No. l72/2025 declared the sample as ‘substandard’ on the basis of the result of impurity (ethylene glycol) above the permissible limits.  
10.Injection Vitamin K1   Each ml contains: Phytomenadione ……… 2 mg  H-18825  M/s Venus Pharma.  23 Km Multan Road Lahore. (DML # 000300)  DDCP Alert No. l72/2025 declared the sample as ‘substandard’ on the basis of the result of sterility test.  
11.SNDOL Suspension 60 ml   Each 5ml contains:  Paracetamol ………. 120 mg  917  M/s S.N.B Pharma (Pvt) Ltd.   Plot No. 142 Industrial Estate Hayatabad Peshawar. (DML # 000759)  DDCP Alert No. l73/2025 declared the sample as ‘substandard’ on the basis of the result of impurity (ethylene glycol) above the permissible limits.  
12.Resgyl Suspension 60 ml   Benzoyl Metronidazole eq. to Metronidazole ……. 200mg / 5ml  4E566  M/s Rasco Pharma (Pvt) Ltd.  5.5 Km Raiwind Road Ali Razabad, Lahore. (DML # 000530)  DDCP Alert No. l73/2025 declared the sample as ‘substandard’ on the basis of the result of impurity (ethylene glycol) above the permissible limits.  
13.Syrup Syandin 60 ml   Each 5ml contains: Loratadine ………… 5 mg  L25E57  M/s Synchro Pharmaceuticals.  77-Industrial Estate Kot Lakhpat Lahore. (DML # 575)  DDCP Alert No. l73/2025 declared the sample as ‘substandard’ on the basis of the result of impurity (ethylene glycol) above the permissible limits.  
14.Injection Neocobal 1 ml Mecobalamin 0.5mg/ml  S-2621  M/s Pulse Pharmaceuticals (Pvt) Ltd.  Mozay Badoke Raiwind Road (Sua Asil Road) Lahore. (DML # 000564)  DDCP Alert No. l73/2025 declared the sample as ‘substandard’ and ‘adulterated’.  
15.Infusion NIDA 100 ML Metronidazole 500mg/100ml  25D055  M/s GMP Pharmaceuticals. 28-Km Sheikhupura Road Lahore. (DML # 000815)  DDCP Alert No. l77/2025 declared the sample as ‘substandard’ on the basis of visible particulate matter.  
16.Metrorise injection Metronidazole 500mg/100ml  LV-2422  M/s Pak Risen Pharmaceuticals. Plot No. 3 Block B Phase-I-II Industrial Estate Hattar. (DML # 000573)  DDCP Alert No. l77/2025 declared the sample as ‘substandard’ on the basis of Bacterial Endotoxin Test.  
17.Infusion Revasol-H 500ml (Hartmann solution)   Each 100 ml contains: Potassium Chloride 0.04gm, Sodium Lactate 0.32gm, Sodium Chloride 0.60gm, Calcium Chloride 2H20 0.027gm  25D1037  M/s Revive Pharmakon.   10-Km Raiwind Road Lahore. (DML # 000819)  DDCP Alert No. l77/2025 declared the sample as ‘substandard’ on the basis of Bacterial Endotoxin Test.  
18.Infusion Parapals 100 ml Paracetamol USP 1g/100ml  PPV-384  M/s Inventor Pharma. Plot No. K/196, S.I.T.E Phase-II, Karachi (DML # 000866)  DDCP Alert No. l77/2025 declared the sample as ‘substandard’ on the basis of visible particulate matter.  
19.Injection Freclomide Metoclopramide …… 10mg/2ml  25MC05  M/s Friends Pharma (Pvt) Ltd. 31-Km Ferozepur Road Lahore. (DML # 000681).  DDCP Alert No. l77/2025 declared the sample as ‘substandard’ on the basis of visible particulate matter & Sterility test.  
20.Syrup Allerphene 120ml   Chlorpheniramine maleate ………………………2mg/5ml  4047  M/s P.D.H Pharmaceuticals (Pvt) Ltd.   19 Km Ferozepur Road Lahore. (DML # 000459)  DDCP Alert No. l79/2025 declared the sample as ‘substandard’ on the basis of the result of impurity (ethylene glycol) above the permissible limits.  
21.Injection Aqua-P 5ml Sterile water for injection 5 mlP-676M/s Ipram International. Plot # 26 SS-3 National Industrial Zone Rawat. (DML # 000551)  DDCP Alert No. l79/2025 declared the sample as ‘substandard’ on the basis of the result of visible particulate matter & Bacterial Endotoxin Test.  
Risk Statement:The above-mentioned batches have been declared substandard due to serious quality defects including sterility failure, presence of bacterial endotoxins, visible particulate matter, and impurities such as ethylene glycol. Use of these defective medicines may lead to severe health risks including infections, sepsis, organ toxicity, or treatment failure.
This alert particularly concerns patients receiving ophthalmic preparations, sterile injections/infusions (including antibiotics, metronidazole, paracetamol, vitamin K, and electrolyte solutions), as well as children and adults using oral syrups and suspensions. Healthcare professionals and the general public are advised to immediately stop use of the affected batches and report any adverse events.
Action Initiated– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market.

– All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company.

Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsmsdra.gov.pk.

Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare ProfessionalsDRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product.  

-Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the
Adverse Event Reporting Form or online through this link.

-Please click here for further information on problem reporting to DRAP.
Advice for Consumers-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product.

-All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.